The same group demonstrated remarkable anti-tumor activity in 40 heavily pre-treated mCRPC patients administered with 100 kBq/kg of [225Ac]Ac-PSMA-617 per three cycles performed every 2 months. This evidence concerns the gene FOLH1 and neoplasm.